- Country: Argentina
- Summary: Paclitaxel 300 mg fco amp con set de infusion vedolizumab 108 mg/068 ml lapicera prellenada pembrolizumab 100 mg / 4 ml fa iv pertuzumab 420 mg fa x 14 ml
- ART Ref No: 133351271
- Deadline: 16 Jan 2026
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: ARS 47396747.76
- Notice Type: Tender
- Document Ref. No.:
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Paclitaxel 300 mg fco amp con set de infusion vedolizumab 108 mg/068 ml lapicera prellenada pembrolizumab 100 mg / 4 ml fa iv pertuzumab 420 mg fa x 14 ml
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINPaclitaxel 300 mg fco amp con set de infusion vedolizumab 108 mg/068 ml lapicera prellenada pembrolizumab 100 mg / 4 ml fa iv pertuzumab 420 mg fa x 14 ml - Argentina Tender
The CEMAFE - SANTA FE OUTPATIENT MEDICAL SPECIALTIES CENTER SANTA FE MEDICAL SPECIALTIES CENTER - CEMAFE, a Government sector organization in Argentina, has announced a new tender for Paclitaxel 300 mg fco amp con set de infusion vedolizumab 108 mg/068 ml lapicera prellenada pembrolizumab 100 mg / 4 ml fa iv pertuzumab 420 mg fa x 14 ml. This tender is published on ArgentinaTenders under ART Ref No: 133351271 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2026-01-16.
The estimated tender value is ARS 47396747.76, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
